Alan B. Lancz & Associates, Inc. Gilead Sciences, Inc. Transaction History
Alan B. Lancz & Associates, Inc.
- $94.4 Million
- Q4 2023
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 10,390 shares of GILD stock, worth $726,884. This represents 0.89% of its overall portfolio holdings.
Number of Shares
10,390
Previous 10,690
2.81%
Holding current value
$726,884
Previous $801,000
4.99%
% of portfolio
0.89%
Previous 0.92%
Shares
5 transactions
Others Institutions Holding GILD
# of Institutions
1,891Shares Held
1BCall Options Held
8.71MPut Options Held
8.02M-
Black Rock Inc. New York, NY123MShares$8.57 Billion0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$8.03 Billion0.17% of portfolio
-
Capital World Investors Los Angeles, CA84.5MShares$5.91 Billion1.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.2MShares$4.28 Billion1.05% of portfolio
-
State Street Corp Boston, MA57.7MShares$4.04 Billion0.19% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $87.7B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...